A phase I randomized, double-blind, placebo-controlled second investigational triple combination therapy trial of of GLPG3067, GLPG2222 and GLPG2737 in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 28 Jun 2018
Price : $35 *
At a glance
- Drugs Galicaftor (Primary) ; GLPG 2737 (Primary) ; GLPG 3067 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Pharmacokinetics
- 28 Jun 2018 According to a Galapagos NV media release, AbbVie has decided not to proceed with this study.
- 28 Jun 2018 Status changed from recruiting to discontinued, according to a Galapagos NV media release.
- 05 Jan 2018 New trial record